spacer
home > ebr > summer 2007 > compatibility
PUBLICATIONS
European Biopharmaceutical Review

ComPatibility

Vaibhav Sarvesh at Frost & Sullivan evaluates the pros and cons of a unified patent system throughout the EU, and suggests a way forward that might end the impasse

The European Union (EU) is an economist’s dream. It was created to synergise the strengths of the European nations and create an economic entity which can have a formidable influence on the world economy. But the very idea of creating a single economic entity poses multiple challenges that must be managed to keep it alive. It involves creating a cordial environment for business, encouraging the individual strengths of the member nations and thus proving the concept of the ‘union’ as the superior model. The most important aspect of creating the right business environment is understanding the nature of the economies of the member nations. In the case of the EU, most of the economies are capital intensive in nature, and thus the future growth of these economies will be driven by innovation. Any future plan for the EU will have to consider creating an encouraging environment for innovators.

An efficient patent system is critical to the development of an innovation-driven industry like biotechnology. The implementation of the long discussed Community Patent System or ComPat (a unitary patent system for the member nations of the EU) is a very important change that the industry is eagerly awaiting, as it competes with the US, Japan and Asian economies to retain and attract innovators. The fact that the present system of patent protection in the EU is four times more expensive than that of the US clearly takes the competitive advantage away from the EU.

Patent protection is one of the most important mechanisms that can help the biotech industry to flourish in any economy. This is especially true for the growth of small- and mediumscale enterprises (SMEs). One way to nurture an innovationbased industry is to provide a limited period of monopoly over an innovation so that the innovators find it lucrative to continue in the industry. This is why an efficient patent system is an absolute necessity to nurture the growth of SMEs, because the most valuable asset these companies own is the patents for their innovations.

EUROPEAN VERSUS US BIOTECH

The implementation of the ComPat will correct various aspects of the biotech industry in Europe. One of the major aspects it will limit is the brain drain – the movement of innovators to the US or other lucrative economic zones in order to secure patents for their innovations. At the same time it will retain and attract investment.

The US biotech industry is a well-developed market with a comparatively efficient patent system, therefore it attracts more investment from multiple sources, including venture capitalists (€2.5 billion in venture capital was raised in 2004 compared to just €1.1 billion in venture capital raised by the European biotech industry). Venture capitalists are a crucial source of investment for the development of the biotech industry and a company’s patent portfolio has great influence over investment from them. A study published by the European Association for Bioindustries stated that the European and US biotech industries both have around 2,000 companies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Vaibhav Sarvesh joined Frost & Sullivan’s research team early this year, and had previously been working as an Analyst in the European Healthcare, Pharma & Biotech team. In the past, Vaibhav has also worked for the business development division of Frost & Sullivan. His role as a Healthcare, Pharma & Biotech Analyst includes assessing and reporting on pharma & biotech markets across Europe, the Middle East and Africa. Vaibhav has a BSc, with a specialisation in Biochemistry, Genetics and Biotechnology. He has also earned a MA in Business Administration from SBS Swiss Business School, Zurich, in collaboration with Alliance Business Academy, Bangalore. His areas of specialisation are international marketing, retail management, market research, rural marketing and marketing communication.
spacer
Vaibhav Sarvesh
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers

ECCRT

ECCRT

The European Centre for Clinical Research Training (ECCRT) is a professional clinical research training provider focusing on the transfer of implementable knowledge for the day-to-day activities of our participants whether being new to the industry, starters on the job, or seasoned professionals. Our mission is to facilitate Clinical Research professionals to excel in their job for the benefit of patients. We aim to achieve this by providing clinical research professionals with competencies to develop new therapies for patients quicker & more efficiently, without jeopardizing quality and safety.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement